Basic Information
| LncRNA/CircRNA Name | TATDN1 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay |
| Sample | Breast cell line (Hs578Bst) and BCa cell lines (MCF-7, MDA-MB-231, and BCap-37), BCa tissues and paracancerous tissues |
| Expression Pattern | up-regulated |
| Function Description | TATDN1 was highly expressed in BCa tissues and cell lines. Upregulation of TATDN1 promoted the proliferative potential and cell cycle progression of MCF-7 and MDAMB-231 cells. Dual-luciferase reporter gene assay indicated that TATDN1 could bind to microRNA-140-3p, which was lowly expressed in BCa. Overexpression of microRNA-140-3p inhibited the proliferative potential and cell cycle progression of MCF-7 and MDA-MB-231 cells. Moreover, microRNA-140-3p partially inhibited the role of TATDN1 in regulating cellular behaviors of BCa cells. NOVA1 was predicted to be the target gene of microRNA-140-3p. Overexpression of NOVA1 partially abolished the inhibitory effects of microRNA-140-3p on proliferation and cell cycle progression of MCF-7 and MDA-MB-231 cells. |
| Pubmed ID | 31298381 |
| Year | 2019 |
| Title | TATDN1 promotes the development and progression of breast cancer by targeting microRNA-140-3p |
External Links
| Links for TATDN1 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |